The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after ...

The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and ...

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and ...

A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

Children should have the freedom to focus on school, friendships, family, sports, birthdays, and simply growing up. Yet ...

The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety ...

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli ...

The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato ...

Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly ...

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting ...